The UBT251 injection for CKD developed by UNITED LAB has received approval for new drug clinical trials from the U.S. FDA
I'm PortAI, I can summarize articles.
United Lab's wholly-owned subsidiary United BioTech (Zhuhai Hengqin) Co., Ltd. has developed the innovative drug UBT251 injection, which has been approved by the U.S. FDA to conduct Phase II clinical trials for chronic kidney disease (CKD). Previously, this indication was approved by the National Medical Products Administration of China on January 20, 2025. UBT251 is a long-acting GLP-1/GIP/GCG tri-target receptor agonist, marking an enhancement in the company's competitiveness in the biopharmaceutical field
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments